AU2002213132A1 - Suppression of cyclin kinase activity for prevention and treatment of infections - Google Patents

Suppression of cyclin kinase activity for prevention and treatment of infections

Info

Publication number
AU2002213132A1
AU2002213132A1 AU2002213132A AU1313202A AU2002213132A1 AU 2002213132 A1 AU2002213132 A1 AU 2002213132A1 AU 2002213132 A AU2002213132 A AU 2002213132A AU 1313202 A AU1313202 A AU 1313202A AU 2002213132 A1 AU2002213132 A1 AU 2002213132A1
Authority
AU
Australia
Prior art keywords
infections
suppression
prevention
treatment
kinase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213132A
Inventor
Thomas Albrecht
Laurent Meijer
Priscilla Schaffer
Luis Schang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
University of Texas System
Original Assignee
University of Pennsylvania Penn
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, University of Texas System filed Critical University of Pennsylvania Penn
Publication of AU2002213132A1 publication Critical patent/AU2002213132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
AU2002213132A 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections Abandoned AU2002213132A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68598600A 2000-10-10 2000-10-10
US09/685,986 2000-10-10
US09685986 2000-10-10
US30418500P 2000-10-11 2000-10-11
US60304185 2000-10-11
US60/304,185 2000-10-11
PCT/US2001/031835 WO2002030410A2 (en) 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections

Publications (1)

Publication Number Publication Date
AU2002213132A1 true AU2002213132A1 (en) 2002-04-22

Family

ID=26973864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213132A Abandoned AU2002213132A1 (en) 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections

Country Status (2)

Country Link
AU (1) AU2002213132A1 (en)
WO (1) WO2002030410A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502172A (en) * 2005-07-28 2009-01-29 ユニバーシティ オブ マサチューセッツ Glucose transport-related genes, polypeptides, and methods of use thereof
BR112023015303A2 (en) 2021-02-01 2023-11-14 Regenxbio Inc METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT
CN117379432B (en) * 2023-12-12 2024-03-08 北京大学 Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
EP0355245A1 (en) * 1988-08-26 1990-02-28 Michel Vandevelde Use of retrovirus reverse transcriptase inhibiting agents
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1998039007A1 (en) * 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
ATE355841T1 (en) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co USE OF PYRAZOLO (3,4-B)PYRIDINE AS A CYCLINE-DEPENDENT KINASE INHIBITOR
EP1079826B1 (en) * 1998-05-29 2003-03-05 CNRS, Centre National de la Recherche Scientifique Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
FR2801216A1 (en) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Use of indirubine derivatives to inhibit 3 beta-glycogen synthase kinase, for the treatment of diabetes, neurodegenerative disorders, manic-depressive disorders, cancers, or parasites
FR2804959B1 (en) * 2000-02-15 2006-04-28 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
AU2001237029A1 (en) * 2000-02-15 2001-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising flavopiridol and their use for hiv therapy

Also Published As

Publication number Publication date
WO2002030410A2 (en) 2002-04-18
WO2002030410A3 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU6174900A (en) Use of flavones, coumarins and related compounds to treat infections
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU3356500A (en) Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2798900A (en) Utilisation of thiadizole derivatives for the prophylactic and therapeutic treatment of infections
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU1794801A (en) Method for treatment and prevention of physiological shock
AU2001257163A1 (en) Glycopeptide antibacterial compounds and methods of using same
AU2002213132A1 (en) Suppression of cyclin kinase activity for prevention and treatment of infections
AU2002228660A1 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
IL137940A0 (en) Treatment or prevention of coccidiosis
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU1618901A (en) Treatment of rosacea
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease
AU2003238175A1 (en) Treatment of serious infections and septic shock
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i